Track topics on Twitter Track topics that are important to you
Intercept Pharmaceuticals Inc. (developing treatments for primary biliary cholangitis, NASH, and primary sclerosing cholangit...
Original Article: Public offerings net $383.4mm for Intercept PharmaceuticalsNEXT ARTICLE
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...